Protecting sight with a simple eye drop.
An innovative and convenient antiangiogenic alternative to invasive intravitreal injections for treating retinal blinding diseases.
THE PROBLEM
Angiogenesis and
vascular permeability drive retinal diseases.
Microvascular retinal diseases such as AMD and DME are the leading causes of irreversible blindness in the developed world. The treatment of these diseases involves inhibiting the vascular endothelial growth factor (VEGF), a potent inducer of angiogenesis and vascular permeability.
Anti-VEGF therapy:
inconvenient & incomplete.
THE CHALLENGES
Invasiveness, inconvenience, unsatisfactory results, and financial burden lead to poor adherence to anti-VEGF treatments. Furthermore, over 50% of patients show persistent disease and fluid and suboptimal vision recovery. This is because VEGF is not the only factor driving the disease.
Significant burden.
Limited effectiveness.
Limited options.
VIAN-c4551
Exceptional ocular penetration and longevity.
Just one daily eye drop of our lead drug maintains potent therapeutic levels in the retina, effectively inhibiting angiogenesis and permeability.
OUR COMPETITIVE EDGE
Seeing beyond VEGF
VIAN lead asset acts selectively on angiogenic endothelial cells to potently inhibit their response to proangiogenic factors such as VEGF and Ang-2. VIAN-c4551 has shown better efficacy and no side effects.
The convenience and the complete antiangiogenic profile unlock market opportunities for VIAN in treating retinal diseases.
Convenient
Topically active.
Complete
Highly potent and effective.
Safe
Selective, specific and innocuous.
Experts in angiogenesis inhibition and eye disease.
-
Juan Pablo Robles Alvarez, M.Sc., Ph.D., is the CEO and Founder of VIAN Therapeutics. With a decade of dedicated research, he made the groundbreaking discovery of a pivotal molecule, now integral to our therapeutic approach. His commitment to advancing ocular healthcare further underscores his pursuit of CEO preparedness through coursework at the UCSF Global Entrepreneurship program, Nucleate, and IndieBio. Dr. Robles' expertise and visionary leadership drive our mission to redefine vision protection.
CEO and Founder
-
Napoleone Ferrara, MD, is a renowned physician-scientist who has left an indelible mark on the field of ophthalmology. His groundbreaking work led to the discovery of vascular endothelial growth factor (VEGF), a pivotal molecule in angiogenesis. Dr. Ferrara's research paved the way for innovative treatments in eye care, transforming the lives of countless individuals suffering from vision-threatening conditions. His invaluable expertise is a guiding force in our mission to redefine ocular healthcare.
Scientific Advisor
-
Carmen Clapp, Ph.D., is a distinguished advisor at VIAN Therapeutics. With a background in physiology and a remarkable research career, she brings invaluable insights to our team. Her pioneering work in discovering vasoinhibin and its impact on angiogenesis has shaped our innovative approach to retinal health. Dr. Clapp's expertise is instrumental in guiding our mission to revolutionize ocular healthcare.
Scientific Advisor
Other advisors and consultants:
Stephanie Marrus, MBA, MA, UCSF. Start-up, and early-stage company strategy
Carolina García Rizo, MS, PhD, MBA.Biotech strategy advisor
Subhadeep Das, PhD, IIT, Science Entrepreneur. Peptide science and therapeutics
Magdalena Zamora, B. Pharm, MS, PhD, UNAM. Identification of angiogenesis inhibitors.
Qianying Zuo, MSTM, PhD, Princeton. Angiogenesis in tumor growth and metastasis
Philipp Sander, GS, Scripps. Biophysical Chemistry and Synthetic Biology
Backed by.
“Convenient treatment and an integral approach to inhibiting angiogenesis are essential to halt the relentless progression of blinding retinal diseases.”
— JUAN PABLO ROBLES, PHD
CEO & Founder
Contact.
Shape the future of vision protection with us.